29th Mar 2022 13:39
SkinBioTherapeutics PLC- Skin health-focused life sciences company - Says pretax loss widens to GBP1.2 million in six months to December 31, from GBP628,241 a year earlier. US market penetration with its only product launched in October 2021, AxisBiotix-Ps, for treating Psoriasis, was slower than expected, company adds. Revenue for the half comes in at GBP21,949, against none a year earlier. For the financial year ending in June, the company expects revenue materially below expectations, it warns.
Current stock price: 37.27 pence, down 18% on Tuesday
12-month change: down 21%
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Skinbiotherap.